Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.45 |
| ▸ | PTGES | O14684 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1532428 | 0.86 | LMNA (0.52) | RECQLLMNAALOX5PTGESPPARG | |
| SCHEMBL1375933 | 0.85 | RECQL (0.62) | RECQLLMNAALOX5PTGESPPARG | |
| SCHEMBL2941326 | 0.85 | RECQL (0.62) | RECQLLMNAALOX5PTGESPPARG | |
| Bicarbonate SCHEMBL8518325 | 0.83 | RECQL (0.60) | RECQLLMNAALOX5PTGESPPARG | |
| Oxalic Acid SCHEMBL10792364 | 0.82 | RECQL (0.58) | RECQLLMNAALOX5PTGESPPARG | |
| SCHEMBL2946253 | 0.80 | RECQL (0.60) | RECQLLMNAALOX5PTGESPPARG | |
| SCHEMBL2946252 | 0.80 | RECQL (0.60) | RECQLLMNAALOX5PTGESPPARG | |
| SCHEMBL28306887 | 0.80 | CES2 (0.53) | RECQLLMNAALOX5PTGESPPARG | |
| SCHEMBL524131 | 0.80 | ALOX5 (0.59) | RECQLLMNAALOX5PTGESPPARG | |
| SCHEMBL1786246 | 0.80 | ALOX5 (0.59) | RECQLLMNAALOX5PTGESPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897058-A | Collagen compositions and methods of use thereof | 现代牧场股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-116847871-A | Skin care compositions and methods of use | 现代牧场股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-110997074-A | Topical compositions for anti-aging benefits | 荷兰联合利华有限公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-110997075-A | Topical compositions for enhancing barrier function | 荷兰联合利华有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-08-05 | — | — | US | disclosed |
| EP-2037872-A2 | COMPOSITIONS COMPRISING BETULONIC ACID | Valtion Teknillinen Tutkimuskeskus (FI) | 2009-03-25 | — | — | EP | disclosed |
| US-20080107613-A1 | Pharmaceutical composition comprising a macrolide t-cell immunomodulator and anti-photoaging agent | NOVARTIS AG (CH) | 2008-05-08 | — | — | US | disclosed |
| WO-2007141392-A2 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| EP-1814546-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MACROLIDE T-CELL IMMUNOMODULATOR AND ANTI-PHOTOAGING AGENT | Novartis AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053699-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MACROLIDE T-CELL IMMUNOMODULATOR AND ANTI-PHOTOAGING AGENT | NOVARTIS AG (CH) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | BET1, PGGT1B, RABGGTB | RECQL 2763/4885LMNA 3692/4885ALOX5 93/4885 |
| US-20080107613-A1 | Pharmaceutical composition comprising a macrolide t-cell immunomodulator and anti-photoaging agent | UNG, TPMT, ERCC1 | RECQL 753/4885LMNA 1182/4885ALOX5 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.